Stock Events

Stock Events

Starpharma 

A$0.68
10
+A$0.07+10.57% Today

Statistics

Day High
0.68
Day Low
0.61
52W High
0.67
52W Low
0.09
Volume
56,205,961
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Apr 988
A$0.02
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

17FebExpected
Q2 2023
Q3 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
-0
-0
0
0
Expected EPS
N/A
Actual EPS
0.002825016229642384

Financials

-203.38%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
9.82MRevenue
-19.98MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SPL.AU. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Lilly(Eli) &
LLY
Mkt Cap840.84B
Eli Lilly competes in the pharmaceutical sector, focusing on drugs that could directly compete with Starpharma's therapeutic products.
Pfizer
PFE
Mkt Cap153.13B
Pfizer operates in similar therapeutic areas as Starpharma, making them direct competitors in the pharmaceutical market.
Merck
MRK
Mkt Cap300.2B
Merck is involved in the development of pharmaceuticals that could compete with Starpharma's product offerings in oncology and infectious diseases.
Johnson & Johnson
JNJ
Mkt Cap574.66B
Johnson & Johnson, through its pharmaceutical division, competes across various therapeutic areas similar to Starpharma.
GSK
GSK
Mkt Cap116.3B
GlaxoSmithKline competes with Starpharma in the development and marketing of pharmaceuticals and healthcare products.
Novartis
NVS
Mkt Cap297.35B
Novartis competes in the global pharmaceutical market, offering products that could directly compete with Starpharma's portfolio.
Abbvie
ABBV
Mkt Cap367.8B
AbbVie operates in the pharmaceutical industry, focusing on areas that overlap with Starpharma's interests, such as oncology.
AMGEN
AMGN
Mkt Cap189.22B
Amgen focuses on biopharmaceuticals, competing with Starpharma in the development of novel treatments for various diseases.
Bristol-Myers Squibb
BMY
Mkt Cap119.69B
Bristol Myers Squibb competes in the pharmaceutical sector, particularly in areas like cancer treatment, which overlaps with Starpharma's focus.
Roche
RHHBY
Mkt Cap322.3B
Roche Holding AG competes with Starpharma in the pharmaceutical and diagnostics market, particularly in oncology and infectious diseases.

About

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Show more...
CEO
Ms. Cheryl Maley B.Sc., M.B.A.
Employees
40
Country
Australia
ISIN
AU000000SPL0

Listings

STU
DE
PQ6.STU
F
DE
PQ6A.F
MU
DE
PQ6.MU
AU
AU
SPL.AU

0 Comments

Share your thoughts

FAQ

What is Starpharma stock price today?▼
The current price of SPL.AU is A$0.68 AUD — it has increased by +10.57% in the past 24 hours. Watch Starpharma stock price performance more closely on the chart.
What is Starpharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Starpharma stocks are traded under the ticker SPL.AU.
Is Starpharma stock price growing?▼
SPL.AU stock has risen by +30.39% compared to the previous week, the month change is a +43.01% rise, over the last year Starpharma has showed a +571.72% increase.
When is the next Starpharma earnings date?▼
Starpharma is going to release the next earnings report on August 26, 2026.
What were Starpharma earnings last quarter?▼
SPL.AU earnings for the last quarter are 0 AUD per share, whereas the estimation was N/A AUD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A AUD per share.
What is Starpharma revenue for the last year?▼
Starpharma revenue for the last year amounts to 9.82M AUD.
What is Starpharma net income for the last year?▼
SPL.AU net income for the last year is -19.98M AUD.
Does Starpharma pay dividends?▼
Yes, SPL.AU dividends are paid annual. The last dividend per share was 0.02 AUD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Starpharma have?▼
As of April 16, 2026, the company has 40 employees.
In which sector is Starpharma located?▼
Starpharma operates in the Health & Wellness sector.
When did Starpharma complete a stock split?▼
Starpharma has not had any recent stock splits.
Where is Starpharma headquartered?▼
Starpharma is headquartered in Abbotsford, Australia.